

Congress of the United States
Washington, DC 20515

August 14, 2015

F. Michael Ball
Chief Executive Officer
Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045

Dear Mr. Ball:

We are conducting an investigation into price increases for drugs used to treat common medical conditions as well as life-threatening illnesses. As part of this investigation, we are examining recent price increases related to two essential cardiovascular drugs, Isuprel and Nitropress, which are used by doctors to treat abnormal heart rhythms, congestive heart failure, and hypertensive episodes.

It is our understanding that Hospira has continued to manufacture these drugs after selling their rights to Marathon Pharmaceuticals in 2013, pursuant to a five-year supply agreement. It is also our understanding that Valeant Pharmaceuticals International assumed this supply agreement when it bought the drugs from Marathon in February 2015, and that Hospira continues to manufacture Isuprel and Nitropress.

In order to better understand the underlying causes of price increases associated with these drugs, we request that you provide the following documents and information:

- (1) any contracts or agreements Hospira entered into relating to the continued supply or manufacture of Isuprel and Nitropress when Marathon Pharmaceuticals acquired the rights to these drugs in 2013;
- (2) any valuations or cost analyses relating to the sale of Isuprel and Nitropress to Marathon Pharmaceuticals;
- (3) any contracts or agreements Hospira has held or currently holds with Valeant Pharmaceuticals International relating to the supply or manufacture of these drugs;
- (4) any sales contracts or purchase agreements for the active pharmaceutical ingredients contained in Isuprel and Nitropress, including any agreements relating to exclusivity, from December 2013 to the present;
- (5) Hospira's expenses relating to the manufacture of Isuprel and Nitropress, as well as the purchase of active pharmaceutical ingredients for these drugs, from December 2013 to the present; and

- (6) a description of any material changes to the supply chain or manufacture of these drugs, including the cost or availability of active pharmaceutical ingredients, from December 2013 to the present.

Please provide the requested documents and information by September 3, 2015.

If you have any questions about this request, please contact Sophie Kasimow with Ranking Member Sanders' staff at (202) 224-5141 or Kelly Christl with Ranking Member Cummings' staff at (202) 225-5051. Thank you for your attention to this important matter.

Sincerely,



Representative Elijah E. Cummings
Ranking Member
Committee on Oversight and Government Reform
United States House of Representatives



Senator Bernard Sanders
Ranking Member
Subcommittee on Primary Health and
Retirement Security
Committee on Health, Education, Labor, and
Pensions
United States Senate

cc: The Honorable Jason Chaffetz
Chairman, House Committee on Oversight and Government Reform